ArticleFrontiers in oncology2026
Acute lymphoblastic leukemia with bone marrow necrosis as the first clinical manifestation: a pediatric case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reports a rare case of a 4-year-old male child with acute lymphoblastic leukemia (ALL) presenting initially with bone marrow necrosis (BMN) as the chief clinical manifestation. The child sought medical attention due to fever, bone pain, and fatigue. Laboratory tests indicated pancytopenia. Initial bone marrow cytomorphology examination revealed disrupted cellular architecture, suggesting possible BMN, and single-site flow cytometry detected no definitive abnormalities, highlighting the diagnostic complexity caused by BMN. Through multi-site bone marrow aspiration and biopsy, the diagnosis was ultimately confirmed as common B-cell ALL (common-B-ALL). Treatment followed the South China Children's Cancer Collaborative Group SCCCG-ALL-2023 protocol, incorporating blinatumomab immunotherapy based on risk stratification. The child responded well to treatment and is currently in the maintenance chemotherapy phase, with minimal residual disease (MRD) monitoring consistently indicating complete remission. This case emphasizes the importance of early recognition of rare presentations like BMN-onset in pediatric ALL, the necessity of multi-site bone marrow examination, and the crucial role of individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.